Immunomodulatory TGF- β Signaling in Hepatocellular Carcinoma.
Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
Trends Mol Med. 2019 Jul 25;:
Authors: Chen J, Gingold JA, Su X
Abstract
Hepatocellular carcinoma (HCC) is an inflammation-induced and chemotherapy-resistant cancer. Dysregulated signaling in the transforming growth factor beta (TGF-β) pathway plays a central role in inflammation, fibrogenesis, and immunomodulation in the HCC microenvironment. This review dissects the genetic landscape of the TGF-β superfamily genes in HCC and discusses the essential effects of this pathway on the tumor immune microenvironment. We highlight the TGF-β signature as a potential biomarker for identifying individualized immunotherapeutic approaches in HCC. An improved understanding of the detailed mechanisms of liver cancer immunogenicity and the specific role of TGF-β in mediating immunotherapy resistance in HCC will provide important insights into HCC immune escape and promote the development of biomarker-derived combination immunotherapies for HCC.
PMID: 31353124 [PubMed - as supplied by publisher]
Source: Trends in Molecular Medicine - Category: Molecular Biology Authors: Chen J, Gingold JA, Su X Tags: Trends Mol Med Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Genetics | Hepatocellular Carcinoma | Immunotherapy | Liver | Liver Cancer | Molecular Biology | Science | Urology & Nephrology